Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia

Fermin Sanchez-Guijo, MD PhD, Sergio Matarraz, Eleni Plata, Miguel Sagüés, Montserrat Cortes, Irena Preloznik Zupan, Monica Crugnola, MD, Giovanni Caocci, MD, Heather Oakervee, BSc, MBBS, MD MRCP, FRCPath, Tobias Gedde-Dahl, Krzysztof Warzocha, Wieslaw W. Jedrzejczak, Slawomira Kyrcz-Krzemien, MD PhD, Alexander Kiani, Sharon Supekar, AnaRita Ferreira, Seema Shah, Juan Luis Steegmann, Michele Baccarani, MD

Blood (2019) 134 (Supplement_1): 4160.

https://doi.org/10.1182/blood-2019-124710

Published: 2019

Journal Articles

Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy

Blood (2019) 134 (Supplement_1): 2935.

https://doi.org/10.1182/blood-2019-129825

Published: 2019

Journal Articles

Sequence of Second Generation Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Patients with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia - Real World Experience in the UK

Jenny Byrne, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Adam J. Mead, MD PhD, Heather Oakervee, BSc, MBBS, MD MRCP, FRCPath, Gavin Campbell, FRCP,FRCPath, Ian Amott, Andrew Goringe, Earnest Heartin, Evangelia Dimitriadou, MD, Ian Pamphlett, Siamak Arami, MD MRCP, FRCPath, Pratap Neelakantan, Rebecca Frewin, Srinivas Pillai, MBBS,MD MRCP, FRCPath, Hugues De Lavallade, Nicholas C.P. Cross, Michael Thompson

Blood (2019) 134 (Supplement_1): 3434.

https://doi.org/10.1182/blood-2019-122893

Published: 2019

Journal Articles

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature

Blood (2018) 132 (20): 2154–2165.

https://doi.org/10.1182/blood-2018-05-849893

Published: 2018

Includes: Supplemental data

Journal Articles

Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34 − fraction

David C. Taussig, Jacques Vargaftig, Farideh Miraki-Moud, Emmanuel Griessinger, Kirsty Sharrock, Tina Luke, Debra Lillington, Heather Oakervee, Jamie Cavenagh, Samir G. Agrawal, T. Andrew Lister, John G. Gribben, Dominique Bonnet

Blood (2010) 115 (10): 1976–1984.

https://doi.org/10.1182/blood-2009-02-206565

Published: 2010

Includes: Supplemental data

Journal Articles

Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis – Results From the UK Amyloidosis Treatment Trial.

Julian Gillmore, Kim Cocks, Simon DJ Gibbs, Prayman T Sattianayagam, Thirusha Lane, Helen Lachmann, Stephen Schey, James D. Cavenagh, Heather Oakervee, Gareth J Morgan, Atul B Mehta, Suzan Bourne, E. Skinner, G. Booth, Philip N Hawkins, Ashutosh D Wechalekar

Blood (2009) 114 (22): 2869.

https://doi.org/10.1182/blood.V114.22.2869.2869

Published: 2009

Journal Articles

A Novel Heat Shock Protein (HSP) 90 Inhibitor KW-2478 shows Activity in B-Cell Malignancies in Vitro and in Vivo.

Simone Juliger, Takayuki Nakashima, Lenushka Maharaj, Toshihiko Ishii, Hiroshi Nakagawa, Yutaka Kanda, Heather Oakervee, James Cavenagh, Shiro Akinaga, Yukimasa Shiotsu, Simon P Joel

Blood (2008) 112 (11): 1625.

https://doi.org/10.1182/blood.V112.11.1625.1625

Published: 2008

Journal Articles

Anti-CD38 antibody–mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells

David C. Taussig, Farideh Miraki-Moud, Fernando Anjos-Afonso, Daniel J. Pearce, Kirsty Allen, Christopher Ridler, Debra Lillington, Heather Oakervee, Jamie Cavenagh, Samir G. Agrawal, T. Andrew Lister, John G. Gribben, Dominique Bonnet

Blood (2008) 112 (3): 568–575.

https://doi.org/10.1182/blood-2007-10-118331

Published: 2008

Includes: Supplemental data

Journal Articles

Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma: Final Results of a Phase I/II Clinical Trial.

Rakesh Popat, DipRCPath, Catherine Williams, FRCPath, Mark Cook, FRCPath, Charles Craddock, FRCPath, Supratik Basu, FRCPath, Charles Singer, FRCPath, Liz Odeh, RGN, Nicola Foot, DipRCPath, Simon Hallam, MRCP, Heather Oakervee, MRCPath, James D. Cavenagh, FRCPath

Blood (2007) 110 (11): 2713.

https://doi.org/10.1182/blood.V110.11.2713.2713

Published: 2007

Journal Articles

PAD Given at Relapse Is More Effective Than VAD Given as Induction Therapy - Results of a Phase II Study.

Treen C. Morris, Paul J. Kettle, Mary B. Drake, Aisleen Brunton, Gordon Cook, Maeve Leahy, Michael O’Dwyer, Helen Enright, Tanya O’Shea, Rakesh Popat, Heather Oakervee, James D. Cavenagh

Blood (2007) 110 (11): 2724.

https://doi.org/10.1182/blood.V110.11.2724.2724

Published: 2007

Journal Articles

Longer Duration of Thalidomide Monotherapy Results in Improved Outcome in Relapsed/Refractory Multiple Myeloma.

Blood (2007) 110 (11): 2725.

https://doi.org/10.1182/blood.V110.11.2725.2725

Published: 2007

Journal Articles

A Phase I/II Trial of Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma.

Rakesh Popat, DipRCPath, Catherine Williams, FRCPath, Mark Cook, FRCPath, Charles Craddock, FRCPath, Supratik Basu, FRCPath, Charles Singer, FRCPath, Liz Odeh, RGN, Nicola Foot, BSc, Heather Oakervee, MRCPath, James D. Cavenagh, FRCPath

Blood (2006) 108 (11): 3542.

https://doi.org/10.1182/blood.V108.11.3542.3542

Published: 2006

Journal Articles

PAD Combination Therapy (PS-341/Bortezomib, Adriamycin and Dexamethasone) for Previously Untreated Patients with Multiple Myeloma.

James D. Cavenagh, MD, Rakesh Popat, MB BS, Nikki Curry, MB BS, Jim Stec, PhD, Treen C. Morris, FRCP, Mary Drake, MRCPath, Samir Agrawal, PhD, Patricia Smith, RGN, David P. Schenkein, MD, Dixie-Lee Esseltine, MD, Heather Oakervee, MRCP

Blood (2004) 104 (11): 1478.

https://doi.org/10.1182/blood.V104.11.1478.1478

Published: 2004

NARROW

Enestpath Leukemic Stem Cell (LSC) Sub-Study: Analyzing Characteristics of LSC-Positive Patients and Impact of Switch from Imatinib to Nilotinib Therapy on LSCs in Patients with Chronic Myeloid Leukemia

Interim Analysis of a Prospective Multicentre Study Using Next Generation Sequencing for Kinase Domain Mutational Analysis in CML Patients on First or Subsequent TKI Therapy

Sequence of Second Generation Tyrosine Kinase Inhibitors (TKIs) in the Treatment of Patients with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia - Real World Experience in the UK

RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature

Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34 − fraction

Cyclophosphamide, Thalidomide and Dexamethasone (CTD) Versus Melphalan Plus Dexamethasone (MD) for Newly-Diagnosed Systemic AL Amyloidosis – Results From the UK Amyloidosis Treatment Trial.

A Novel Heat Shock Protein (HSP) 90 Inhibitor KW-2478 shows Activity in B-Cell Malignancies in Vitro and in Vivo.

Anti-CD38 antibody–mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells

Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma: Final Results of a Phase I/II Clinical Trial.

PAD Given at Relapse Is More Effective Than VAD Given as Induction Therapy - Results of a Phase II Study.

Longer Duration of Thalidomide Monotherapy Results in Improved Outcome in Relapsed/Refractory Multiple Myeloma.

A Phase I/II Trial of Bortezomib, Low Dose Intravenous Melphalan and Dexamethasone for Patients with Relapsed Multiple Myeloma.

PAD Combination Therapy (PS-341/Bortezomib, Adriamycin and Dexamethasone) for Previously Untreated Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only